Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine

The antidiabetic drug metformin has been proposed to affect non-alcoholic fatty liver disease (NAFLD) through its effects on intestinal microbiota and barrier function. However, so far most studies focused on long-term effects and more progressed disease stages. The aim of this study was to assess i...

Descripción completa

Detalles Bibliográficos
Autores principales: Brandt, Annette, Hernández-Arriaga, Angélica, Kehm, Richard, Sánchez, Victor, Jin, Cheng Jun, Nier, Anika, Baumann, Anja, Camarinha-Silva, Amélia, Bergheim, Ina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491483/
https://www.ncbi.nlm.nih.gov/pubmed/31040374
http://dx.doi.org/10.1038/s41598-019-43228-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6491483/
https://www.ncbi.nlm.nih.gov/pubmed/31040374
http://dx.doi.org/10.1038/s41598-019-43228-0

Ejemplares similares